after intervention correlates with major hepatic complications suggesting that these factors are important to hepatic health.
after intervention correlates with major hepatic complications suggesting that these factors are important to hepatic health.
Summary: This study investigates the risks factors which might lead to death or hepatic failure postpancreatectomy who required endovascular treatment to treat hemorrhage or pseudoaneurysm. Forty patients were found but 12 were eliminated from analysis since the hepatic artery was not treated. This left 28 patients with intervention required of the common hepatic artery or its distal arteries. The diagnosis was clinical (n ¼ 26), noted as blood in the abdominal drain or NG tube (n ¼ 19), hemorrhagic shock (n ¼ 8), and hematemesis and/or melena in six patients. In 20 of these 21 patients, hemorrhage and/or pseudoaneurysm were apparent on computed tomography (CT) imaging. Two patients did not have an imminent clinical bleeding issues but imaging noted a pseudoaneurysm in fluid collections and with irregular shapes concerning for rupture. Eight patients had a platelet count <50K and/or international normalized ratio >1.5. CT imaging was used to determine a replaced hepatic artery and significant portal vein stenosis (>50% on portal-phase imaging). In five patients, arterial and portal venous findings were based on angiography since CT was not available. Four or 5-F sheath were used for diagnostic imaging, hemorrhage or pseudoaneurysms found in the common hepatic artery or gastroduodenal stump with no replaced hepatic artery were treated with either stent or perfusion catheters to preserve hepatopetal flow via hepatic arteries. Stents were a self-expanding covered metallic stent to cover the lesion or bare-metal stent with coil embolization through the stent into the bleeding site. Alternatively, a perfusion catheter was placed to perfuse the hepatic artery and a coaxial catheter used microcoils to embolize the bleeding site. In patients with a replaced hepatic artery, coil embolization with or without n-butyl cyanoacrylate injection into the common hepatic artery was performed with expectation of collateral flow providing adequate liver perfusion through the replaced hepatic through communicating arcades. Post intervention angiography confirmed the absence of bleeding and maintenance of at least one hepatic artery flow directly or via collaterals. Maximal duration of follow-up was one year with follow-up until death or LTF but few specifics are provided. Hepatic failure was a major complications and present if liver enzymes were $ 1000 U/L or gradually increase > 10 mg/dL within 7 days. Hepatic abscess was a CT diagnosis in addition to inflammatory markers. Recurrent bleeding and the need for additional interventions were also assessed. The majority of bleeding was from the common hepatic or GDA stump (n ¼ 19) or proper hepatic artery (n ¼ 4), right hepatic (n ¼ 3) and left hepatic artery (n ¼ 2). Portal vein stenosis was noted in 57%. A covered stent was used in 1 case, bare-metal with embolization in 5 cases, perfusion catheter assisted embolization in 5, and coil embolization in 17. Technical success was 100%. Hepatopedal arterial flow was noted in 93% via collaterals and 64 direct flow. Major hepatic complications were noted in 9 cases; 7 hepatic failures, 4 abscess and 2 both. Repeat bleeding requiring endovascular therapy (EVT) occurred in 7 cases with a second episode in 3 at the same site and 4 at a different site. Seventy-one percent were alive at discharge, mortality was 29% and interval to death was a median of 25.5 months. Long-term data is not specifically provided nor is data provided in a life-table method. Hemorrhagic shock (n ¼ 8: 2 alive/6 deceased; P ¼ .0018) and coagulopathy (n ¼ 8: 2 alive/6 deceased; P ¼ .0018) at onset were significantly associated with death prior to discharge. Portal vein stenosis, lack of hepatopetal flow, or repeat procedures (4 alive/3 deceased) did not statistically effect discharge mortality. Overall, eight patients had coagulopathy (two did not experience hepatic failure and survived, while six experienced hepatic failure and died; P ¼ .003 in multivariant analysis), and 10 patients demonstrated a lack of visualization of hepatopetal arterial flow through hepatic arteries (P ¼ .01, multivariant analysis); both were statistically associated with major hepatic complications. The presence of portal vein stenosis noted in 16 patients also were associated with major hepatic complications (P ¼ .03).
Comments: This study suggests that shock and coagulopathy prior to intervention to stop a bleeding event postpancreatectomy are associated with increased mortality. This may be expected based on what we know from the general trauma literature. Those factors associated with major hepatic eventsereduced blood supply from direct arterial flow and reduced portal blood floweare also intuitive since both would decrease liver perfusion. Unfortunately, the study can only suggest that these factors are important since the small numbers and extensive statistical analyses provide for significant statistical error which may or may not be clinically significant end points. The technical variations are too numerous to provide sufficient data to determine which technique performs better. There is essentially no long-term clinical follow-up provided, so little can be determined with regard to long-term success using these techniques. Only variables that could easily be collected preoperatively were recorded and used for analysis. It was specifically stated that the 30-day hospital mortality was available in the database. Variables were entered into a multivariable logistic regression model to identify independent predictors of 30-day mortality. Linear regression analysis was then undertaken to determine an equation to predict risk of 30-day mortality. Six hundred and forty-nine patients underwent rAAA repair, of which 247 were treated by endovascular aneurysm repair (EVAR) (38.1%) and 402 with open repair (61.9%). The overall mortality was 30.7% (33.4% open, 26.2% EVAR). Multivariate modeling demonstrated that the primary determinants of 30-day mortality were advanced age (>76 vs #76 years old; odds ratio [OR], 2.91), elevated serum creatinine (>1.5 vs #1.5 mg/dL; OR, 1.57), and lowest reported systolic blood pressure (BP <70 vs >70 mm Hg; OR, 2.65). The linear regression model (C-statistic of 0.69) determined a % 30-day mortality ¼ 14 + 22 (age >76 years) + 9 (creatinine >1.5 mg/dL) + 20 (BP <70 mm Hg). Using this model, patients can be stratified into specific estimated 30-day mortality risk groups from a low of 14% to a high of 65%.
Predicting Mortality of Ruptured Abdominal Aortic Aneurysms in the Era of Endovascular Repair
Comments: For the elderly patient with renal insufficiency presenting in shock, a high 30-day mortality with associated morbidity may change the decision for aggressive intervention and/or transfer to a regional center for care. This study includes both open and EVAR cases; the latter were not included in prior models to determine rAAA mortality risk and so this model is more applicable to our modern approach to the care for these patients. Conclusions: In pseudoxanthoma elasticum (PXE), a vascular phenotype can be identified with a distribution of arterial calcifications that is distinct from hospital controls and involves arterial calcifications in the legs, intracranial internal carotid arteries, and arteries of the arms.
Summary: PXE is a rare monogenetic disease caused by mutations in the ABCC6 gene that leads to calcification of the skin, the eyes, and the arterial walls. This mutation results in inefficient mediators of ATP secretion in the liver, resulting in low levels of inorganic pyrophosphate with progressive ectopic calcifications. It is currently not known how arterial calcifications are distributed in the body and how the distribution is different from control patients. In this study, 104 PXE patients from the Dutch PXE cohort were compared to 93 hospital controls (scans obtained for melanoma staging, fever of unknown origin, or suspicion of malignancy). All patients underwent low-dose (<3 mSv) full-body computed tomography without contrast to determine prevalence and severity of arterial calcifications per arterial location. The computed tomography scans were scored on a reproducible semiquantitative scale with four calcification categories. PXE patients (38/104 males) were 54 6 13 years old and controls (45/93 males) were 54 6 16 years old, with statistically lower incidence of renal failure (0% vs 7%) and higher blood pressure (137/80 vs 130/76) in those with PXE. Arterial calcifications were
